Opthea Limited's Megan Baldwin speaks with Proactive during the ASX Small and Mid-Cap Conference, March 2022. It's a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases.
Opthea with Proactive at the ASX Small and Mid-Cap Conference
